<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317796</url>
  </required_header>
  <id_info>
    <org_study_id>BK-MD-201</org_study_id>
    <nct_id>NCT02317796</nct_id>
  </id_info>
  <brief_title>Adult Subjects With Uncontrolled Type 2 Diabetes</brief_title>
  <official_title>A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melior Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bukwang Pharmaceutical, Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Melior Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study
      of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

        1. To assess the safety, tolerability and initial anti-diabetic activity of MLR-1023 in
           subjects with uncontrolled mild to moderate type 2 diabetes mellitus

        2. To evaluate the pharmacokinetics of MLR-1023 and the major metabolite, MLR-1023-M1
           following 28 days of repeat dosing

      Design and Outcomes

      The study is a randomized, double blind, placebo-controlled, parallel group study of MLR-1023
      in adult subjects with uncontrolled type 2 diabetes mellitus who are on diet and exercise
      therapy.

      A subset of subjects per dose group will have additional samples analyzed to measure signs of
      MLR-1023.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PPG AUC0-3h in a MMTT between Days 1 and 29.</measure>
    <time_frame>29 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose in dose groups from Day 1 to Day 29, Day 36</measure>
    <time_frame>36 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fructosamine level from Day 1 to Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin from Day 1 to Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycated albumin from Day 1 to Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day 1 to Day 29 in insulin sensitivity using HOMA-R (HOMA-R = fasting plasma insulin (mU/l) * fasting plasma glucose (mmol/l) / 22.5)</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Day 1 to Day 29 in beta-cell function using HOMA-B (HOMA-B = 20 * fast- ￼ing plasma insulin (mU/l) / [fasting plasma glucose (mmol/l) - 3.5])</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C between Days 1 and Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL-C, HDL-C, TG between Days 1 and Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight between Days 1 and Day 29</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between placebo and MLR-1023 dose groups in PPG AUC0-3h Days 1 and 29.</measure>
    <time_frame>29 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg q.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg b.i.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg q.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg b.i.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLR-1023</intervention_name>
    <description>Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>100 mg q.d.</arm_group_label>
    <arm_group_label>100 mg b.i.d.</arm_group_label>
    <arm_group_label>200 mg q.d.</arm_group_label>
    <arm_group_label>200 mg b.i.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with uncontrolled T2DM who have received diet and exercise therapy for at
             least 3 months prior to screening, aged ≥ 18 - ≤ 75 years

          2. Females must be post-menopausal, unable to conceive, or test negative for pregnancy
             via blood test and use barrier contraception

          3. BMI ranging from ≥ 20 to ≤ 40 kg/m2

          4. Fasting plasma glucose values of up to 240 mg/dL at screening, after wash-out (visit
             2) and after placebo run-in (visit 3)

          5. (i) naïve or (ii) currently using and discontinued metformin or (iii) no prior
             exposure to anti-diabetic agents other than metformin ≥ 6 months prior to screening

        Exclusion Criteria:

          1. History of Type 1 diabetes

          2. History of more than 1 episode of severe hypoglycemia within 6 months prior to
             screening, or a current diagnosis of hypoglycemia unawareness.

          3. Hospitalizations or Emergency room visits that would impact patient safety or data
             interpretation:

               1. Due to poor glucose control in the 6 months prior to screening or

               2. Any bariatric surgical procedures for weight loss.

          4. Significant change of body weight (&gt;10%) in the 3 months before screening

          5. Proliferative retinopathy or maculopathy within the 6 months before screening or
             requiring acute treatment, or severe neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melior Pharmaceuticals I &amp; Bukwang Pharm. Co., Ltd.</last_name>
    <role>Study Director</role>
    <affiliation>Melior Pharmaceuticals I &amp; Bukwang Pharm. Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Melior Pharmaceuticals I &amp; Bukwang Pharm. Co., Ltd.</name>
      <address>
        <city>USA and South Korea</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2014</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

